Literature DB >> 14991511

Changes in drug susceptibility and toxin genes in Staphylococcus aureus isolated from blood cultures at a university hospital.

Hirohisa Endo1, Yoshimi Higurashi, Katsuko Okuzumi, Shigemi Hitomi, Satoshi Kimura.   

Abstract

We studied changes in toxin-producing genes and drug susceptibility in Staphylococcus aureus isolated from blood cultures at the University of Tokyo Hospital between 1980-1984 (six mecA gene-positive methicillin resistant S. aureus [MRSA] strains and 20 mecA gene-negative methicillin-susceptible S. aureus [MSSA] strains) and 1999 (11 MRSA and 20 MSSA strains). The prevalence of strains with toxin-producing genes increased from 66.7% to 90.9% in MRSA, and from 30.0% to 55.0% in MSSA during the interval. Among toxin-producing gene-positive S. aureus, the dominant strains shifted from those with the enterotoxin (ET) - A gene in 1980-1984 to those with both the toxic shock syndrome toxin-1 and the ET-C genes in 1999. All strains were susceptible to vancomycin and teicoplanin. Mupirocin and arbekacin inhibited all strains at concentrations of less than or equal to 0.5 micro g/ml and 4 micro g/ml, respectively. More than half of the MRSA strains in 1999 were considered to be nonsusceptible to flomoxef. Because almost all MRSA and more than half of MSSA among recently isolated strains possessed the toxin-producing genes, we should pay attention to whether toxin-related diseases caused by MRSA and MSSA are increasing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991511     DOI: 10.1007/s10156-003-0276-0

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  1 in total

1.  Variations in amount of TSST-1 produced by clinical methicillin resistant Staphylococcus aureus (MRSA) isolates and allelic variation in accessory gene regulator (agr) locus.

Authors:  Miki Nagao; Akira Okamoto; Keiko Yamada; Tadao Hasegawa; Yoshinori Hasegawa; Michio Ohta
Journal:  BMC Microbiol       Date:  2009-03-10       Impact factor: 3.605

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.